ARTICLE | Clinical News
ILX-651: Started Phase I trials
January 8, 2001 8:00 AM UTC
Ilex Oncology Inc. (ILXO), San Antonio, Texas Product: ILX-651 Business: Cancer Therapeutic category: Cell proliferation Target: Tubulin Description: Orally active synthetic pentapeptide analog of do...